These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 9412162)

  • 21. Premenstrual disorders: bridging research and clinical reality.
    Yonkers KA; Pearlstein T; Rosenheck RA
    Arch Womens Ment Health; 2003 Nov; 6(4):287-92. PubMed ID: 14628181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of premenstrual dysphoric disorder.
    Rapkin AJ; Lewis EI
    Womens Health (Lond); 2013 Nov; 9(6):537-56. PubMed ID: 24161307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The measurement of premenstrual mood symptoms.
    Steiner M; Streiner DL; Steinberg S; Stewart D; Carter D; Berger C; Reid R; Grover D
    J Affect Disord; 1999 Jun; 53(3):269-73. PubMed ID: 10404713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term fluoxetine treatment of late luteal phase dysphoric disorder.
    Pearlstein TB; Stone AB
    J Clin Psychiatry; 1994 Aug; 55(8):332-5. PubMed ID: 8071300
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medical (fluoxetine) and psychological (cognitive-behavioural therapy) treatment for premenstrual dysphoric disorder: a study of treatment processes.
    Hunter MS; Ussher JM; Cariss M; Browne S; Jelley R; Katz M
    J Psychosom Res; 2002 Sep; 53(3):811-7. PubMed ID: 12217456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of central serotonergic dysfunction in the aetiology of premenstrual dysphoric disorder: therapeutic implications.
    Parry BL
    CNS Drugs; 2001; 15(4):277-85. PubMed ID: 11463133
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective serotonin reuptake inhibitors and treatment of premenstrual dysphoric disorder.
    Finfgeld DL
    Perspect Psychiatr Care; 2002; 38(2):50-60. PubMed ID: 12132631
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Double-blind, placebo-controlled pilot study of adjunctive quetiapine SR in the treatment of PMS/PMDD.
    Jackson C; Pearson B; Girdler S; Johnson J; Hamer RM; Killenberg S; Meltzer-Brody S
    Hum Psychopharmacol; 2015 Nov; 30(6):425-34. PubMed ID: 26193781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of managed care charges among patients treated with selective serotonin reuptake inhibitors for premenstrual dysphoric disorder.
    Endicott J; McLaughlin TP; Grudzinski AN
    J Clin Psychiatry; 2003 Dec; 64(12):1511-6. PubMed ID: 14728114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective serotonin reuptake inhibitors for premenstrual syndrome.
    Brown J; O' Brien PM; Marjoribanks J; Wyatt K
    Cochrane Database Syst Rev; 2009 Apr; (2):CD001396. PubMed ID: 19370564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective serotonin reuptake inhibitors for premenstrual syndrome.
    Marjoribanks J; Brown J; O'Brien PM; Wyatt K
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD001396. PubMed ID: 23744611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management strategies for premenstrual syndrome/premenstrual dysphoric disorder.
    Jarvis CI; Lynch AM; Morin AK
    Ann Pharmacother; 2008 Jul; 42(7):967-78. PubMed ID: 18559957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Duloxetine for premenstrual dysphoric disorder: a pilot study.
    Mazza M; Harnic D; Catalano V; Janiri L; Bria P
    Expert Opin Pharmacother; 2008 Mar; 9(4):517-21. PubMed ID: 18312154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression.
    Krystal A; Fava M; Rubens R; Wessel T; Caron J; Wilson P; Roth T; McCall WV
    J Clin Sleep Med; 2007 Feb; 3(1):48-55. PubMed ID: 17557453
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of metergoline on symptoms in women with premenstrual dysphoric disorder.
    Roca CA; Schmidt PJ; Smith MJ; Danaceau MA; Murphy DL; Rubinow DR
    Am J Psychiatry; 2002 Nov; 159(11):1876-81. PubMed ID: 12411222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial.
    Cohen LS; Soares CN; Yonkers KA; Bellew KM; Bridges IM; Steiner M
    Psychosom Med; 2004; 66(5):707-13. PubMed ID: 15385695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Premenstrual syndrome no progesterone; premenstrual dysphoric disorder no serotonin deficiency.
    van Leusden HA
    Lancet; 1995 Dec; 346(8988):1443-4. PubMed ID: 7490987
    [No Abstract]   [Full Text] [Related]  

  • 38. [Assessment of premenstrual dysphoric disorder symptoms: population of women in Casablanca].
    McHichi alami Kh; Tahiri SM; Moussaoui D; Kadri N
    Encephale; 2002; 28(6 Pt 1):525-30. PubMed ID: 12506265
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Premenstrual syndrome in adolescents: diagnosis and treatment.
    Rapkin AJ; Mikacich JA
    Pediatr Endocrinol Rev; 2006 Jan; 3 Suppl 1():132-7. PubMed ID: 16641847
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effective open-label treatment of premenstrual dysphoric disorder with venlafaxine.
    Hsiao MC; Liu CY
    Psychiatry Clin Neurosci; 2003 Jun; 57(3):317-21. PubMed ID: 12753573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.